Searched for
ABRAXANE
HSBC bullish on Indian pharma stocks for 2025The steady generic pricing is a tailwind and execution of key launches like gAbraxane for Cipla will determine the path of US sales in 2025.12 Dec, 2024, 05.40 AM IST- Cipla shares zoom nearly 10% as USFDA classifies Goa facility for voluntary actionCipla's shares surged 9.8% after the USFDA classified its Goa facility inspection as Voluntary Action Indicated (VAI), allowing for critica...31 Oct, 2024, 10.04 AM IST
- Cipla stock in focus after Q2 PAT beats estimates. Should you buy, sell or hold?Cipla's shares are in focus as the company reported a 15% YoY increase in consolidated net profit to Rs 1,303 crore for Q2 2024. Revenue ro...30 Oct, 2024, 09.05 AM IST
- Fundamental Radar | Cipla upgraded to “buy” on 5 major growth tailwinds: Motilal OswalCipla recorded an 8% growth in sales on the back of the launch of the generic version of Revlimid and gained market share in lanreotide, al...25 Sep, 2023, 09.43 AM IST
- Cipla sticks to 21-22% operating profit guidance for FY23, posts Rs 789 crore profit in Q2Cipla reported a multi-quarter high of $179 million in revenue and 25% YoY growth led by the successful launch of a generic version of the ...04 Nov, 2022, 08.12 PM IST
- Maruti, IHCL, Godrej Consumer are among Jefferies' top picksJefferies said the company's margins could jump to 31-32% for FY24-25 against 13% in FY22. "During Covid, IHCL has deployed several measure...13 Sep, 2022, 06.00 AM IST
- USFDA rules against Sun Pharma Advanced Research Co's appeal regarding cancer drug applicationThe Office of New Drugs (OND) of the US Food and Drug Administration (FDA) has denied the company's appeal of the Complete Response Letter ...23 Feb, 2021, 07.41 PM IST
- SPARC plunges 10% as USFDA rejects application for cancer drug TaclantisThe company informed this to the exchanges after market hours of Tuesday.12 Feb, 2020, 03.55 PM IST
- Panacea Biotec tanks 6% after CARE downgrades firmCurrently, the m-cap of the company stands at Rs 1,508.61 crore.08 Dec, 2017, 04.09 PM IST
- Glenmark, Particle Sciences to develop generic cancer drugThe partnership will develop and market a generic version of Celgene's ABRAXANE which is used in treatments of breast and lung cancers.19 Sep, 2016, 06.03 PM IST
- Sun Pharma gets DGCI nod for breast cancer drugSun Pharma Advanced Research Company today said it has received the approval of the DGCI for its medicine for treatment of breast cancer.23 Jan, 2014, 10.57 PM IST
- Panacea Biotec to launch breast cancer drugPanacea Biotec will soon launch a generic version of Abraxis Bioscience's breast cancer medicine Abraxane at half the price of the original...11 Feb, 2011, 05.28 AM IST
- Natco to launch cancer drug as min stays DCGI orderThe original maker of the drug, American firm Abraxis Bioscience had complained about the side effects of Natco’s version of the medicine.11 Jan, 2010, 04.09 AM IST
- Natco Pharma faces criminal actionThe country’s top drug regulator plans to initiate criminal proceedings against Hyderabad-based Natco Pharma for selling “substandard” brea...20 Oct, 2009, 04.20 AM IST
- Biocon launches breast cancer drugBiotech company Biocon said it has launched the drug Abraxane, used in the treatment of breast cancer.18 Jul, 2008, 08.16 PM IST
- Biocon receives DCGI nod to market AbraxaneLeading biotech company Biocon Ltd has received approval from the Drug Controller General of India (DCGI) to market breast cancer drug Abra...18 Oct, 2007, 02.00 PM IST
- Biocon to market Abraxis' breast cancer drug in IndiaBiocon Ltd on Thursday announced it has entered into a licensing agreement with US-based Abraxis BioScience Inc for selling 'Abraxane' in I...09 Aug, 2007, 04.54 PM IST
Load More
